Dexmedetomidine + Propofol
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Conscious Sedation
Conditions
Conscious Sedation
Trial Timeline
Nov 1, 2005 → Aug 1, 2006
NCT ID
NCT00318955About Dexmedetomidine + Propofol
Dexmedetomidine + Propofol is a approved stage product being developed by Pfizer for Conscious Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT00318955. Target conditions include Conscious Sedation.
What happened to similar drugs?
0 of 2 similar drugs in Conscious Sedation were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04237792 | Approved | Completed |
| NCT00538616 | Phase 1/2 | Completed |
| NCT00318955 | Approved | Completed |
Competing Products
2 competing products in Conscious Sedation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI | Eisai | Phase 3 | 40 |
| Dexmedetomidine | Orion Corporation | Phase 3 | 29 |